Gynovin

Gynovin is a combined oral contraceptive tablet containing the synthetic estrogen ethinylestradiol and the progestin gestodene. Marketed in the European Union, each tablet delivers a fixed dose of these hormones to provide reliable birth control. The product is prescription‑only and is taken orally once daily as directed by a healthcare professional. It is formulated to inhibit ovulation, thicken cervical mucus, and modify the endometrial lining, thereby reducing the chance of pregnancy.

Gynovin is indicated for women who seek a reliable, reversible method of preventing pregnancy.

- Prevention of pregnancy when taken as a combined oral contraceptive. - Regulation of menstrual cycle and reduction of dysmenorrhea. - Management of acne associated with hormonal fluctuations. - Decrease in the risk of ovarian cyst formation. - May be used to control heavy menstrual bleeding under medical supervision.

Like all hormonal contraceptives, Gynovin may cause side effects; most are mild and transient.

Common: - Nausea or mild stomach upset. - Headache or migraine‑like pain. - Breast tenderness or enlargement. - Spotting or breakthrough bleeding between periods. - Mood changes or mild depression. - Decreased libido.

Serious: - Blood clots in veins or lungs (deep vein thrombosis, pulmonary embolism). - Stroke or transient ischemic attack. - Severe hypertension or hypertensive crisis. - Liver dysfunction or jaundice. - Allergic reactions such as rash, swelling, or anaphylaxis.

Before prescribing Gynovin, clinicians should evaluate individual risk factors and counsel patients on safety considerations.

- History of thromboembolic disorders, stroke, or myocardial infarction. - Smoking, especially in women over 35 years of age. - Uncontrolled hypertension or diabetes with vascular complications. - Current or past breast, liver, or estrogen‑dependent cancers. - Liver disease that impairs hormone metabolism. - Use of certain anticonvulsants or antibiotics that reduce contraceptive efficacy. - Pregnancy or breastfeeding status should be confirmed before initiation.

Gynovin can interact with other medicines, affecting its effectiveness or increasing health risks.

Avoid: - Combined hormonal contraceptives with other estrogen‑containing products (e.g., hormone replacement therapy). - Strong CYP3A4 inducers such as rifampin, carbamazepine, phenytoin, or St. John’s wort. - Certain antiviral agents (e.g., protease inhibitors) that may alter hormone levels. - Selective serotonin reuptake inhibitors (SSRIs) that may affect platelet function.

Use with caution: - Antifungal azoles (ketoconazole, itraconazole) that can increase hormone concentrations. - Some antibiotics (e.g., tetracycline, metronidazole) that may affect gut flora. - Herbal supplements like ginseng that could modify metabolism. - Medications that increase blood pressure (e.g., decongestants) requiring monitoring. - Anticoagulants (warfarin) may have altered effect; monitor INR.